Metabolic Targets in the Crosshairs

“Mitochondria are emerging as idealized targets for anti-cancer drugs. One reason for this is that although these organelles are inherent to all cells, drugs are being developed that selectively target the mitochondria of malignant cells without adversely affecting those of normal cells. Such anticancer drugs destabilize cancer cell mitochondria and these compounds are referred to as mitocans, classified into several groups according to their mode of action and the location or nature of their specific drug targets. Many mitocans selectively interfere with the bioenergetic functions of cancer cell mitochondria, causing major disruptions often associated with ensuing overloads in ROS production leading to the induction of the intrinsic apoptotic pathway. This in-depth review describes the bases for the bioenergetic differences found between normal and cancer cell mitochondria, focusing on those essential changes occurring during malignancy that clinically may provide the most effective targets for mitocan development. A common theme emerging is that mitochondrially mediated ROS activation as a trigger for apoptosis offers a powerful basis for cancer therapy. Continued research in this area is likely to identify increasing numbers of novel agents that should prove highly effective against a variety of cancers with preferential toxicity towards malignant tissue, circumventing tumor resistance to the other more established therapeutic anti-cancer approaches”. Follow the links:

Targeting Cancer Metabolism: Dietary and Pharmacologic Interventions

Natural Compounds as Regulators of the Cancer Cell Metabolism

Bioenergetic pathways in tumor mitochondria as targets for cancer therapy and the importance of the ROS-induced apoptotic trigger

Choosing between glycolysis and oxidative phosphorylation: A tumor’s dilemma?

Targeting Cell Metabolism In Chronic Lymphocytic Leukaemia (CLL); A Viable Therapeutic Approach?

Stalling the Engine of Resistance: Targeting Cancer Metabolism to Overcome Therapeutic Resistance

Is Cancer a Metabolic Disease?

Cancer as a Metabolic Disease

Targeting mitochondria for cancer therapy

Mitochondrial permeability transition pore as a selective target for anti-cancer therapy

Mitochondrial uncoupling and the reprograming of intermediary metabolism in leukemia cells

Mitocans as Novel Agents for Anticancer Therapy: An Overview

Apoptosis: from biology to therapeutic targeting

Metabolic targets in the crosshairs

Metabolic targets in the cross hairs

Betulinic Acid – an underrated natural compound with profound anti-cancer properties

Betulinic acid structure

Betulinic acid structure

Betulinic acid (3Ī², hydroxy-lup-20(29)-en-28-oic acid) is a pentacyclic triterpenoid of plant origin that is widely distributed in the plant kingdom throughout the world. It is known for itsĀ antiretroviral, antimalarial, anti-inflammatory, and anti-cancer properties and has been used in folk medicine for a variety of ailments.

Here are a few links to the relevant research:

Betulinic acid as a potent and complex antitumor phytochemical: a minireview (abstract only)

Betulinic acid induces a novel cell death pathway that depends on cardiolipin modification (abstract only)

A Review on Preparation of Betulinic Acid and Its Biological Activities

Anti-Inflammatory and Anticancer Properties of Birch Bark-Derived Betulin: Recent Developments

Betulinic acid-induced apoptosis in leukemia cells

Betulinic acid-induced mitochondria-dependent cell death is counterbalanced by an autophagic salvage response

Betulinic acid induces cytochrome c release and apoptosis in a Bax/Bak-independent, permeability transition pore dependent fashion

Betulinic Acid for Cancer Treatment and Prevention

Anticancerous Efficacy of Betulinic acid: An Immunomodulatory Phytochemical

Potential Sources:

Betulinic Acid Pro Liposomal

Z Natural Foods